RxDoctor Payments Data

Leslie Iverson, PA

Physician Assistant · Sandy, UTNPI 1417967035

Payments from drug & device makers

$2,825in general payments, 2019–2025

Across 102 payments — averaging $27.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$547
  • Dexcom, Inc.$424
  • Novartis$273
  • Esperion Therapeutics, Inc.$233
  • Lilly USA, LLC$180
  • Novo Nordisk$152
  • plus $1K from 18 others

What the payments were for

  • Food & beverage$2,813100%
  • Education$120%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,825 in reported general payments places this provider in the 85th percentile of 1,543 physician assistant providers in Utah.

See all physician assistant providers in Utah

Medicare billing

Part B allowed, 2024
$4,736
Medicare patients
51
Services billed
58

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin59$66,622
EliquisApixaban45$51,609
Repatha SureclickEvolocumab54$41,466
FarxigaDapagliflozin Propanediol32$33,204
OzempicSemaglutide22$27,639
MounjaroTirzepatide22$24,682
XareltoRivaroxaban12$9,876
Ezetimibe78$2,183
Rosuvastatin Calcium82$1,431
Potassium Chloride31$890
Flecainide Acetate14$815
Metoprolol Succinate42$808
Atorvastatin Calcium42$614
Amlodipine Besylate59$411
Losartan Potassium41$407

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$24$66,62259 claims
PfizerEliquis$18$51,60945 claims
Novo NordiskOzempic$152$27,63922 claims
Lilly USA, LLCMounjaro$180$24,68222 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,543 physician assistant providers in Utah.

Other physician assistant in Sandy

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →